BETA

- Beta Drugs received regulatory approvals for its oncology portfolio in Azerbaijan across multiple dosage forms including injectables, tablets, capsules, and oral suspensions. - The company has already filed 15 oncology product dossiers and expects another 15 to be ready for filing within the next month. - Beta Drugs aims to secure initial oncology business from Azerbaijan during the current financial year.

- Concall Schedule - Concall Date: September 17, 2026 - Concall Time: 4:00 pm IST - Beta Drugs Ltd. will participate in the Valorem CXO Meet, a virtual group meeting with Valorem Advisors. - The company achieved a 5-year revenue CAGR of 27% and EBITDA CAGR of 25%. - Beta Drugs is targeting a ~25% revenue CAGR through FY30.

- The 21st Annual General Meeting (AGM) of Beta Drugs Limited will be held on Wednesday, 30th September, 2026, at 10:30 a.m. at its registered office. - The Notice of AGM and Annual Report for FY 2025-26 will be submitted to the exchange.

- Board Meeting held on 3rd September 2026 approved the calling of the 21st Annual General Meeting (AGM). - The AGM is scheduled for Wednesday, 30th September 2026, at 10:30 A.M. - Book Closure Period is from 24th September 2026 to 30th September 2026. - Approved the appointment of Charu Jindal & Co as Cost Auditor and V.K. Srivastva & Associates as Internal Auditor for FY 2026-27. - Re-appointed Statutory Auditor M/s Khurana Sharma and Co for FY 2026-27 to 2027-28. - Re-appointed Mr. Ashutosh Shukla as Whole-Time Director from 20th January 2027 to 19th January 2032.

- Board approved the allotment of 35,383 Bonus Equity Shares of face value INR 10 each to holders of Compulsorily Convertible Debentures (CCDs) upon their conversion into Equity Shares. - Decision made at the Board meeting on August 18, 2026.

- Consolidated Revenue ₹125.55 Cr vs ₹100.21 Cr (▲25.28% YoY) - EBITDA ₹27.37 Cr vs ₹19.71 Cr (▲38.86% YoY) - PAT ₹16.49 Cr vs ₹11.70 Cr (▲40.94% YoY) - EBITDA Margin 21.80% vs 19.67% (▲213 bps)

- Consolidated Revenue ₹125.55Cr vs ₹100.21Cr (▲25.3% YoY) - EBITDA (excl. other income) ₹27.37Cr vs ₹19.70Cr (▲38.9% YoY) - PAT ₹16.49Cr vs ₹11.70Cr (▲40.9% YoY) - EBITDA Margin 21.80% vs 19.66% (▲214bps)

- Trading window closed for Directors, Officers, Designated Employees, and their immediate relatives. - Closure effective from July 1, 2026. - Reopens 48 hours after the declaration of Un-Audited Financial Results for Q1 ended June 30, 2026.